- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07932717
Comprehensive Lung Health (CLUES)
Comprehensive Lung Health Screening and Its Utility for Early Risk and Disease Stratification
Respiratory illnesses are a leading cause of morbidity and mortality worldwide, yet their prevalence in the general population remains poorly characterized. Computed tomography (CT) is the most effective diagnostic tool for identifying respiratory illnesses that cause changes to the lung parenchyma, such as pulmonary infections, fibrosis, and nodules. The diagnostic power of CT led the US Preventive Services Task Force (USPSTF) to issue lung cancer screening guidelines. In this prospective, observational cohort study, the study team will recruit 10,000 individuals aged 21 to 85 years, stratified into three cohorts: Cohort 1 (Medical Indication Group), Cohort 2 (Guideline-Based Screening Group), and Cohort 3 (Asymptomatic Research Low-Dose CT [LDCT] Group). The primary analysis will estimate the baseline cross-sectional prevalence of LDCT-detectable pulmonary findings in Cohort 3. Secondary analyses will compare baseline LDCT findings across all three cohorts and evaluate baseline associations between risk/exposure variables and CT findings. Exploratory follow-up analyses will use clinical data from the electronic health record (EHR), as available, for up to 5 years after the baseline/index CT. This study has the potential to transform health screening strategies, reduce disease burden, and improve health outcomes across diverse populations.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Lindsay Summers
- Numéro de téléphone: 312-921-2957
- E-mail: lindsay.summers@nm.org
Lieux d'étude
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60611
- Recrutement
- Northwestern Medicine
-
Chercheur principal:
- Ankit Bharat, MD
-
Contact:
- Lindsay Summers
- Numéro de téléphone: 312-921-2957
- E-mail: lindsay.summers@nm.org
-
Sous-enquêteur:
- Momen Wahidi, MD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
All Cohorts:
•Adults 21 through 85 years of age.
Cohort 1:
•Clinical indication for chest CT, such as suspected lung pathology, abnormal chest imaging, or pulmonary symptoms requiring further evaluation. Cohort 1 activities are routine clinical care; research activity is secondary data use.
Cohort 2:
•Individuals who currently meet USPSTF criteria for LDCT lung cancer screening. Cohort 2 activities are routine clinical care; research activity is secondary data use.
Cohort 3:
- Asymptomatic individuals who:
- Do not have a clinical indication for chest CT
- Do not meet current USPSTF criteria for LDCT lung cancer screening
- Able to provide informed consent
Exclusion Criteria:
All Cohorts:
•Individuals below the age of 21 and above the age of 85.
Cohort 3:
- Meets USPSTF guideline-based indications for LDCT lung cancer screening or has a clinical indication for chest CT.
- Any chest CT within the prior 2 years
- Pregnancy
- In active surveillance or treatment for a current cancer diagnosis, or a recent cancer diagnosis requiring intervention within 5 years of the baseline assessment.
- Unable to provide informed consent or lacks decision-making capacity
- McGaw medical students, residents, and fellows, consistent with NU/FSM policy, to reduce coercion or undue influence. Employees may participate only under the safeguards described in the vulnerable populations section.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Dépistage
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Aucune intervention: Cohort 1 (Medical Indication Group)
Adults 21 through 85 years of age with a clinical reason for chest CT, such as suspected lung pathology, abnormal chest imaging, or pulmonary symptoms requiring further evaluation. Cohort 1 participants undergo CT and follow-up as part of routine clinical care. Study activity is limited to secondary use of routine-care data under waiver of consent and HIPAA authorization. |
|
|
Aucune intervention: Cohort 2 (Guideline-Based Screening Group)
Adults 21 through 85 years of age who meet current USPSTF criteria for LDCT lung cancer screening. Cohort 2 participants undergo screening and follow-up as part of routine clinical care. Study activity is limited to secondary use of routine-care data under waiver of consent and HIPAA authorization. |
|
|
Comparateur actif: Cohort 3 (Asymptomatic Research LDCT Group)
Adults 21 through 85 years of age who are asymptomatic, do not have a clinical indication for chest CT, and do not meet current USPSTF lung cancer screening criteria. Cohort 3 participants will provide informed consent and HIPAA authorization before undergoing a single LDCT of the chest billed to the study. |
A low-dose CT scan is an X-ray procedure where a high-speed computer is used to make multiple images of your chest area using the least amount of radiation possible without reducing the diagnostic quality of the exam.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Primary Endpoint
Délai: For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
|
Baseline prevalence of CT-detectable pulmonary abnormalities in Cohort 3. |
For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Secondary Endpoint 1
Délai: For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
|
Comparative baseline prevalence of pulmonary findings across Cohorts 1, 2, and 3. |
For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
|
|
Secondary Endpoint 2
Délai: For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
|
Prevalence and reported severity of coronary artery calcification in Cohort 3 and across cohorts, using the final radiology report categories, such as absent/present or none/mild/moderate/severe when available. |
For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
|
|
Secondary Endpoint 3
Délai: For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
|
Prevalence of bone-density-related abnormalities or vertebral compression fracture findings across all three cohorts using the final radiology report terminology. |
For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
|
|
Secondary Endpoint 4
Délai: For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
|
Associations between baseline defined variables and LDCT-detectable findings. |
For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
|
|
Secondary Endpoint 5
Délai: 5 years
|
EHR-derived outcomes for up to 5 years after baseline/index LDCT, including clinically documented diagnoses, additional imaging, procedures, treatments, and mortality as available. |
5 years
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Exploratory Endpoint 1
Délai: 6 years
|
Subgroup analyses by age, sex, race/ethnicity, smoking status, and exposure categories. |
6 years
|
|
Exploratory Endpoint 2
Délai: 6 years
|
Exploratory prediction models if event counts support model development. |
6 years
|
|
Exploratory Endpoint 3
Délai: 6 years
|
Descriptive analyses of downstream clinical evaluation after baseline CT findings. |
6 years
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Ankit J Bharat, MD, Northwestern Medicine Canning Thoracic Institute
- Chercheur principal: Momen J Wahidi, MD, Northwestern Medicine Canning Thoracic Institute
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- STU00223477
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Upon PI approval, de-identified, coded data may be shared with other investigators conducting IRB-approved projects to establish a longitudinal data repository to support future IRB-approved research on early detection, prevention, and management of pulmonary and cardiothoracic conditions. Genetic testing, biospecimen collection, quantitative imaging re-analysis, or other analyses are not currently planned. Recipients will be required to adhere to institutional data protection standards.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .